학술논문

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment
Document Type
Article
Source
In: Blood Cancer Journal. (Blood Cancer Journal, February 2021, 11(2))
Subject
Language
English
ISSN
20445385